Advertisement
Advertisement
NRXP
NRX Pharmaceuticals, Inc. Common Stock
3.08
USDSponsored
+0.02
+0.65%
May 08, 15:58 UTC -4
Closed
After-Market
3.08
0.00
-0.16%
NRXP Earnings Reports
Positive Surprise Ratio
NRXP beat 7 of 15 last estimates.
47%
Next Report
In 3 Days
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$38.10M
/$0.42
Implied change from Q4 25 (Revenue/ EPS)
+3775.58%
/-4300.00%
Implied change from Q1 25 (Revenue/ EPS)
--
/-300.00%
NRX Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Mar 23, 2026, NRXP reported earnings of -0.01 USD per share (EPS) for Q4 25, missing the estimate of 0.00 USD, resulting in a -361.54% surprise. Revenue reached 983.00 thousand, compared to an expected 7.68 million, with a -87.19% difference. The market reacted with a -6.25% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of 0.42 USD, with revenue projected to reach 38.10 million USD, implying an decrease of -4300.00% EPS, and increase of 3775.58% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
Xeris Biopharma Holdings, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+296.08%
Ironwood Pharmaceuticals, Inc. - Class A
Report Date
May 07, 2026 For Q1 26
Estimate
$0.24
Actual
$0.24
Surprise
-1.96%
SIGA Technologies Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Profound Medical Corp. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.19
Surprise
+25.75%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
ZOETIS INC.
Report Date
May 07, 2026 For Q1 26
Estimate
$1.63
Actual
$1.53
Surprise
-6.19%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
NewAmsterdam Pharma Company N.V. Ordinary Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.40
Surprise
+20.32%
FAQ
What were NRX Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, NRX Pharmaceuticals, Inc. Common Stock reported EPS of -$0.01, missing estimates by -361.54%, and revenue of $983.00K, -87.19% below expectations.
How did the market react to NRX Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -6.25%, changed from $2.08 before the earnings release to $1.95 the day after.
When is NRX Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for NRX Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 6
analysts, NRX Pharmaceuticals, Inc. Common Stock is expected to report EPS of $0.42 and revenue of $38.10M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement